{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:20:15Z","timestamp":1794327615508,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109383","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T01:01:50Z","timestamp":1775437310000},"page":"109383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab"],"prefix":"10.1016","volume":"216","author":[{"given":"Rita","family":"Chiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-3864","authenticated-orcid":false,"given":"Marco","family":"Russano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3338-4671","authenticated-orcid":false,"given":"Giacomo","family":"Leva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-2230","authenticated-orcid":false,"given":"Rita","family":"Emili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fiorenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"De Lisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Elisa","family":"Gulini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marcantognini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bisonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-1890","authenticated-orcid":false,"given":"Annamaria","family":"Ruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109383_b0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: management of non-small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109383_b0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109383_b0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/genes16030307","article-title":"Integrative In Silico Analysis to Identify Functional and Structural Impacts of nsSNPs on Programmed Cell Death Protein 1 (PD-1) Protein and UTRs: potential Biomarkers for Cancer Susceptibility","volume":"16","author":"Al-Nakhle","year":"2025","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109383_b0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5603\/MRJ.a2021.0022","article-title":"Liquid biopsy in targeting gene polymorphism related to the response within immunocheckpoint inhibitors therapeutic regimen","volume":"6","author":"Boguszewska-Byczkiewicz","year":"2021","journal-title":"Med Res J."},{"key":"10.1016\/j.lungcan.2026.109383_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102662","article-title":"Review \u2013 the impact of pharmacogenetics on the outcome of immune checkpoint inhibitors","volume":"122","author":"De Joode","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2026.109383_b0030","doi-asserted-by":"crossref","unstructured":"Yang M, Liu Y, Zheng S, et al. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies. Aging. Published online March 27, 2024. doi:10.18632\/aging.205689.","DOI":"10.18632\/aging.205689"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109383_b0035","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00592-018-1152-9","article-title":"Rs2227982 and rs2227981 in PDCD1 gene are functional SNPs associated with T1D risk in East Asian","volume":"55","author":"Gu","year":"2018","journal-title":"Acta Diabetol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109383_b0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00251-017-1015-5","article-title":"PD-1 and cancer: molecular mechanisms and polymorphisms","volume":"70","author":"Salmaninejad","year":"2018","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109383_b0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.imlet.2014.09.001","article-title":"PD-1 mRNA expression is associated with clinical and viral profile and PD1 3\u2032-untranslated region polymorphism in patients with chronic HBV infection","volume":"162","author":"Zhang","year":"2014","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.lungcan.2026.109383_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672521","article-title":"PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in patients with Metastatic Melanoma","volume":"12","author":"Parakh","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109383_b0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng1020","article-title":"A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109383_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152448","article-title":"Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: a Meta-Analysis Involving twelve Case-Control Studies","volume":"11","author":"Dong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109383_b0065","unstructured":"Wagner M, Tupikowski K, Jasek M, et al. SNP-SNP Interaction in Genes Encoding PD-1\/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma. www.mdpi.com\/journal\/cancers."},{"key":"10.1016\/j.lungcan.2026.109383_b0070","first-page":"11","article-title":"Immune Checkpoint Molecules\u2014Inherited Variations as Markers for Cancer Risk","author":"Wagner","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109383_b0075","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10875-010-9450-1","article-title":"Association between Hepatitis B Viral Burden in Chronic Infection and a Functional Single Nucleotide Polymorphism of the PDCD1 Gene","volume":"30","author":"Zheng","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.lungcan.2026.109383_b0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejca.2020.11.035","article-title":"PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade","volume":"144","author":"Yoshida","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109383_b0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3892\/ol.2024.14277","article-title":"Implication of PD-L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PD-1 blockades: a retrospective exploratory study","volume":"27","author":"Gong","year":"2024","journal-title":"Oncol. Lett."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109383_b0090","first-page":"1","article-title":"Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer patients","volume":"2017","author":"Nomizo","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109383_b0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00432-024-06081-x","article-title":"The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study","volume":"151","author":"Suminaga","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109383_b0100","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3892\/mco.2014.358","article-title":"PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer","volume":"2","author":"Sasaki","year":"2014","journal-title":"Mol Clin Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109383_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e20625","article-title":"Clinical impact of single nucleotide polymorphisms (SNPs) in PDCD1 in patients with non-small cell lung cancer (NSCLC) receiving anti-PD1 immunotherapy","volume":"43","author":"Dimitrakopoulos","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109383_b0110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/cancers13061412","article-title":"A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?","volume":"13","author":"Eldafashi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109383_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109383_b0120","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.3390\/biomedicines13092246","article-title":"Genetic Variants and Soluble Isoforms of PD-1\/PD-L1 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma (PDAC) Susceptibility and Prognosis","volume":"13","author":"Hassan","year":"2025","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109383_b0125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/15257770.2023.2253276","article-title":"Elevated programmed cell death-1 protein\/ligand (PD-1\/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the chinese cohort","volume":"43","author":"Yang","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109383_b0130","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.18632\/aging.102845","article-title":"PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population","volume":"12","author":"Zang","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.lungcan.2026.109383_b0135","doi-asserted-by":"crossref","first-page":"S756","DOI":"10.1016\/j.annonc.2020.08.1249","article-title":"1126P Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in patients treated with immune checkpoint blockers for metastasized melanoma","volume":"31","author":"Hassel","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109383_b0140","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168318","article-title":"Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade","volume":"134","author":"Hayashi","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109383_b0145","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00262-023-03464-w","article-title":"Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors","volume":"72","author":"Himuro","year":"2023","journal-title":"Cancer Immunol Immunother CII."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109383_b0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: from Bedside to Bench and Back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"},{"issue":"D1","key":"10.1016\/j.lungcan.2026.109383_b0155","doi-asserted-by":"crossref","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","article-title":"JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles","volume":"52","author":"Rauluseviciute","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109383_b0160","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","article-title":"A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma","volume":"187","author":"Pozniak","year":"2024","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109383_b0165","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1039\/C6MB00851H","article-title":"System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer","volume":"13","author":"Donakonda","year":"2017","journal-title":"Mol. Biosyst."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109383_b0170","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/epi-2020-0208","article-title":"TheDNA methylation landscape of PD-1 (PDCD1) and adjacent lncRNA AC131097.3 in head and neck squamous cell carcinoma","volume":"13","author":"Bockhorst","year":"2021","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109383_b0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12935-023-02872-3","article-title":"The role of LncRNAs in tumor immunotherapy","volume":"23","author":"Pan","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109383_b0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/curroncol32060365","article-title":"KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: a Systematic Review and Meta-Analysis","volume":"32","author":"Markovi\u0107","year":"2025","journal-title":"Curr Oncol Tor Ont."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109383_b0185","article-title":"Differences between lung adenocarcinoma and lung squamous cell carcinoma: driver genes, therapeutic targets, and clinical efficacy","volume":"12","author":"Shen","year":"2024","journal-title":"Genes Dis."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:21:41Z","timestamp":1782663701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S0169500226004447"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109383","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109383"}}